Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Trifluoromethanesulfonic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 2/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL17318233 | 1.00 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1FFAR3LCKFYN | |
| Trifluoromethanesulfonic Acid SCHEMBL1698310 | 1.00 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1FFAR3LCKFYN | |
| Trifluoromethanesulfonic Acid SCHEMBL10796158 | 1.00 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1FFAR3LCKFYN | |
| Trifluoromethanesulfonic Acid SCHEMBL6288403 | 0.97 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1FFAR3LCKFYN | |
| Trifluoromethanesulfonic Acid SCHEMBL17508492 | 0.97 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1FFAR3LCKFYN | |
| Trifluoromethanesulfonic Acid SCHEMBL5093696 | 0.94 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1FFAR3LCKFYN | |
| Trifluoromethanesulfonic Acid SCHEMBL261406 | 0.94 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1FFAR3LCKFYN | |
| Trifluoromethanesulfonic Acid SCHEMBL7647499 | 0.90 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1CA1CA2CA7 | |
| Trifluoromethanesulfonic Acid SCHEMBL2167128 | 0.89 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1FFAR3LCKFYN | |
| Trifluoromethanesulfonic Acid SCHEMBL28053484 | 0.85 | ALDH1A1 (0.43) | ALDH1A1L3MBTL1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016069722-A1 | IONIC CROSS-LINKED POLYMERIC FILMS FOR GAS SEPARATION | CARNEGIE MELLON UNIVERSITY (US) | 2016-05-06 | — | — | WO | claimed |
| US-8906135-B1 | Method of purifying a gas stream using 1,2,3-triazolium ionic liquids | U.S. DEPARTMENT OF ENERGY (US) | 2014-12-09 | — | — | US | claimed |
| CN-110757682-A | Method for recycling waste circuit boards in full-component mode through two-step method | 中国科学院山西煤炭化学研究所 | 2020-02-07 | — | — | CN | disclosed |
| US-10300438-B2 | Ionic cross-linked polymeric films for gas separation | CARNEGIE MELLON UNIVERSITY (US) | 2019-05-28 | — | — | US | disclosed |
| US-9890315-B2 | Use of polylysine as a shale inhibitor | BASF SE (DE) | 2018-02-13 | — | — | US | disclosed |
| US-20180021742-A1 | Ionic Cross-Linked Polymeric Films for Gas Separation | U.S. DEPARTMENT OF ENERGY | 2018-01-25 | — | — | US | disclosed |
| EP-2737000-B1 | USE OF HYPERBRANCHED POLYLYSINE AS SHALE INHIBITOR | BASF SE (DE) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016069722-A1 | IONIC CROSS-LINKED POLYMERIC FILMS FOR GAS SEPARATION | CARNEGIE MELLON UNIVERSITY (US) | 2016-05-06 | — | — | WO | disclosed |
| CN-103917623-A | Use of hyperbranched polylysine as shale inhibitor | BASF SE | 2014-07-09 | — | — | CN | disclosed |
| EP-2737000-A1 | USE OF HYPERBRANCHED POLYLYSINE AS SHALE INHIBITOR | BASF SE (DE) | 2014-06-04 | — | — | EP | disclosed |
| US-20130123148-A1 | USE OF POLYLYSINE AS A SHALE INHIBITOR | BASF SE (DE) | 2013-05-16 | — | — | US | disclosed |
| WO-2013013889-A1 | USE OF HYPERBRANCHED POLYLYSINE AS SHALE INHIBITOR | BASF SE (DE) | 2013-01-31 | — | — | WO | disclosed |
| EP-2197868-B1 | HYDROXYMETHYLFURFURAL ETHERS FROM SUGARS OR HMF AND MIXED ALCOHOLS | FURANIX TECHNOLOGIES BV (NL) | 2011-04-27 | — | — | EP | disclosed |
| EP-1915345-A1 | FLUORO SUBSTITUTED 2-OXO AZEPAN DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007020190-A1 | FLUORO SUBSTITUTED 2-OXO AZEPAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20050043379-A1 | LTA4H Modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043379-A1 | LTA4H Modulators | LTA4H, LTB4R, LTB4R2 | ALDH1A1 1306/4885L3MBTL1 1782/4885FFAR3 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.